Pregabalin prescription in terminally ill cancer patients receiving specialist palliative care in acute hospital

Pregabalin prescription in terminally ill cancer patients receiving specialist palliative care in acute hospital - Pregabalin prescription in terminally ill cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022507

Enrollment

200

Registered

2016-05-28

Start date

2016-05-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic cancer-related pain

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Our subjects comprised cancer patients who died during their hospital stay.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Information including the prescriber, reasons for the prescription, initial dose, maintenance dose, administration period, weight, creatinine clearance (Ccr) calculated from the Cockcroft-Gault formula, if pregabalin had been discontinued, the reason for its discontinuation, and the dose of opioid drugs before and after the discontinuation of pregabalin was extracted from the electronic medical records of patients prescribed pregabalin.We investigated the dose of opioids administered before and after the discontinuation of pregabalin. The half-life of pregabalin according to renal function is 5-48 hours, as stated on the package insert. Therefore, based on its excretion from the body, patients who survived 4 days or more after the discontinuation of pregabalin were targeted.	—

Measure

Time frame

Information including the prescriber, reasons for the prescription, initial dose, maintenance dose, administration period, weight, creatinine clearance (Ccr) calculated from the Cockcroft-Gault formula, if pregabalin had been discontinued, the reason for its discontinuation, and the dose of opioid drugs before and after the discontinuation of pregabalin was extracted from the electronic medical records of patients prescribed pregabalin.We investigated the dose of opioids administered before and after the discontinuation of pregabalin. The half-life of pregabalin according to renal function is 5-48 hours, as stated on the package insert. Therefore, based on its excretion from the body, patients who survived 4 days or more after the discontinuation of pregabalin were targeted.

—

Countries

Japan

Contacts

Public ContactRyo Yajima

Nippon Medical School Hospital Section of Pharmaceutical Services

r-yajima@nms.ac.jp+81-3-3822-2131

Outcome results